Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

BACKGROUND Immune responses mediated by IgE are important in the pathogenesis of allergic asthma. A recombinant humanized monoclonal antibody (rhuMAb-E25) forms complexes with free IgE and blocks its interaction with mast cells and basophils. We studied the efficacy of rhuMab-E25 as a treatment for moderate-to-severe allergic asthma. METHODS After a 4-week run-in period, we randomly assigned 317 subjects (age range, 11 to 50 years) who required inhaled or oral corticosteroids (or both) to receive either placebo or one of two regimens of rhuMAB-E25: high-dose rhuMAb-E25 (5.8 microg per kilogram of body weight per nanogram of IgE per milliliter or low-dose rhuMAb-E25 (2.5 microg per kilogram per nanogram of IgE per milliliter) intravenously on days 0 (half a dose), 4 (half a dose), and 7 (full dose) and then once every 2 weeks thereafter for 20 weeks. For the first 12 weeks of the study, the subjects continued the regimen of corticosteroids they had received before enrollment. During the following eight weeks, the doses of corticosteroids were tapered in an effort to discontinue this therapy. The primary outcome measure was an improvement in the asthma symptom score at 12 weeks, according to a 7-point scale, in which a score of 1 indicated no symptoms and a score of 7 the most severe symptoms. RESULTS A total of 106 subjects were assigned to receive a high dose of rhuMAb-E25, 106 were assigned to receive a low dose, and 105 were assigned to receive placebo. At base line, the mean asthma symptom score was 4.0. After 12 weeks of therapy, the mean (+/-SE) scores were 2.8+/-0.1 in the high-dose group (P=0.008) and 2.8+/-0.1 in the low-dose group (P=0.005), as compared with 3.8+/-0.1 in the placebo group. At 20 weeks, the mean scores were 2.7+/-0.1 in both the high-dose group (P=0.048) and the low-dose group (P=0.14), as compared with 2.9+/-0.1 in the placebo group. More subjects in the two rhuMAb-E25 groups were able to decrease or discontinue their use of corticosteroids than in the placebo group, but only some of the differences were significant. After 20 weeks, serum free IgE concentrations decreased by a mean of more than 95 percent in both rhuMAb-E25 groups. The therapy was well tolerated. After 20 weeks, none of the subjects had antibodies against rhuMAb-E25. CONCLUSIONS A recombinant humanized monoclonal antibody directed against IgE has potential as a treatment for subjects with moderate or severe allergic asthma.

[1]  Adkinson Nf.  Immunotherapy for Allergic Rhinitis , 1999 .

[2]  R. Dockhorn,et al.  Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[3]  J. Bousquet,et al.  Anti-IgE therapy for asthma. , 1997, American journal of respiratory and critical care medicine.

[4]  L. Boulet,et al.  Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. , 1997, American journal of respiratory and critical care medicine.

[5]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[6]  S. Galli.  The Mast Cell: A Versatile Effector Cell for a Challenging World , 1997 .

[7]  A. Buist,et al.  National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. , 1996, American journal of respiratory and critical care medicine.

[8]  P. Barnes.  Is immunotherapy for asthma worthwhile? , 1996, The New England journal of medicine.

[9]  L. Presta,et al.  Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. , 1996, Biochemistry.

[10]  S. Shire,et al.  Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. , 1995, Biochemistry.

[11]  L. Presta,et al.  Inhibition of allergic reactions with antibodies to IgE. , 1995, International archives of allergy and immunology.

[12]  L. Presta,et al.  Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. , 1995, International archives of allergy and immunology.

[13]  L. Presta,et al.  Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. , 1994, The Journal of allergy and clinical immunology.

[14]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.

[15]  G. Guyatt,et al.  Measuring quality of life in asthma. , 1993, The American review of respiratory disease.

[16]  Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene , 1992, The Journal of experimental medicine.

[17]  M. Sears,et al.  Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. , 1991, The New England journal of medicine.

[18]  R. Davies,et al.  Inflammatory cells in the airways in mild asthma. , 1988, BMJ.

[19]  P. O'Byrne,et al.  Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. , 1987, The American review of respiratory disease.

[20]  M. Kaliner.  Late phase reactions. , 1986, New England and regional allergy proceedings.

[21]  N. Thomson,et al.  Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. , 1982, The Journal of allergy and clinical immunology.

[22]  G. Gleich,et al.  The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease? , 1982, The Journal of allergy and clinical immunology.

[23]  E. Hey,et al.  CONTROLLED TRIAL OF HYPOSENSITISATION TO DERMATOPHAGOIDES PTERONYSSINUS IN CHILDREN WITH ASTHMA , 1978, The Lancet.

[24]  G. Solley,et al.  The late phase of the immediate wheal and flare skin reaction. Its dependence upon IgE antibodies. , 1976, The Journal of clinical investigation.